Sign In
Buy AZYO
$1.49
+0 (+0%)
At Close: Dec 05, 2023
Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
04:38pm, Tuesday, 15'th Nov 2022
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Ca
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
04:05pm, Wednesday, 17'th Aug 2022
SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming I
Aziyo Biologics (AZYO) CEO Randy Mills on Q2 2022 Results - Earnings Call Transcript
05:13am, Saturday, 13'th Aug 2022
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Leigh Salvo - IR Kevin Rakin - Executive Chairman Randy Mills - CEO Matthew Fergus
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
12:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022
08:05pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated
Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022
04:05pm, Thursday, 28'th Jul 2022
SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated p
Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.
Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?
10:54am, Wednesday, 20'th Jul 2022
Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.
Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?
08:15am, Monday, 27'th Jun 2022 Zacks Investment Research
Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?
05:24am, Monday, 27'th Jun 2022
Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO
08:05pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated
Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Monday, 09'th May 2022 Zacks Investment Research
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2022 Results - Earnings Call Transcript
08:12pm, Monday, 09'th May 2022
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Fina
Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results
08:05pm, Monday, 09'th May 2022 GlobeNewswire Inc.
SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated
